TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent prior to any study specific procedures~2. Patients between the age of 30 to 79~3. Non-ST elevation Acute coronary syndrome with successful everolimus eluting stent implantation (with TIMI flow grade 3 after the procedure)~Exclusion Criteria:~1. Hypersensitivity to pitavastatin~2. Unable to perform OCT and NIRS~3. Serum creatinine \> 2.0 mg/dL.~4. Steroid or hormone replacement therapy~5. Hemoglobin A1c \>9%~6. Type 1 diabetes~7. Decreased serum platelet level (\< 100,000/uL)~8. Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin~9. Life expectancy less than a year~10. Renal failure requiring dialysis or anticipated need for dialysis during the course of the study~11. Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study~12. Involvement in the planning and/or conduct of the study~13. Left ventricular ejection fraction \< 40%~14. Hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase \> twice the upper limit)~15. Gastrointestinal disorder such as Crohn's disease~16. Alcohol abuse~17. Known pregnancy, breast-feeding, or intend to become pregnant during the study period

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Low dose 1mg pitavastatin (Type: ACTIVE_COMPARATOR): pitavastatin 1mg which is considered low dose statin will be administered for 36 months
- High dose 4mg pitavastatin (Type: ACTIVE_COMPARATOR): pitavastatin 4mg which is considered high dose statin will be administered for 36 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D, Chronic Kidney Disease (CKD) and the Microcirculation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. eGFR between 15 and 60 ml/min/1.73m2~2. Serum 25 (OH) vitamin D levels \<30nmol/L~3. No evidence of diabetes mellitus (fasting blood sugar \<7.1, not taking any diabetic medication)~4. Not receiving haemo or peritoneal dialysis~5. No dialysis therapy within the last 3 months~6. Age \> 18 years and \< 80 years~7. Patient agrees not use any medications (prescribed or over-the-counter including herbal remedies) judged to be clinically significant by the Principal Investigator during the course of the study.~8. Able to understand and sign the written Informed Consent Form.~9. Able and willing to follow the Protocol requirements.~Exclusion Criteria:~1. Currently receiving oral ergocalciferol at any dose~2. Received IM ergocalciferol therapy within last 3 months~3. Receiving renal replacement therapy of any type or having recently received any form of dialysis (within 3 months)~4. Pacemaker or any other implanted cardiac device~5. Serum calcium above 2.6 mmol/L at screening~6. Pregnant or lactating~7. Known hypersensitivity to ergocalciferol~8. Patient known to have a condition which predisposes to hypercalcaemia (multiple myeloma, sarcoidosis, other granulomatous disease)~9. Initial blood pressure of \>160/100 mmHg~10. History of significant liver disease or cirrhosis~11. Anticipated requirement for dialysis in 6 months~12. Malabsorption, severe chronic diarrhea, or ileostomy~13. Known diagnosis of hypervitaminosis D~14. Known to have diabetes mellitus~15. Known to have renal calculi~16. Known to have systemic sclerosis, Raynaud's phenomenon or other disease associated with known microcirculatory dysfunction~17. Concurrent participation in any other research study~18. Unwilling or unable to complete study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Ergocalciferol (oral) (Type: ACTIVE_COMPARATOR): ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo at same dose schedule as ergocalciferol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV criteria for bipolar I (manic or mixed) or mania for at least 4 weeks~* CGAS less than or equal to 60~* Good physical health~Exclusion Criteria:~* Schizophrenia or any pervasive developmental disorder~* Major medical or neurological disease~* History of addiction to illicit substances or alcohol or drug abuse within the last 4 weeks~* IQ less than 70~* Pregnancy or breast-feeding~* Unacceptable methods of contraception~* In-patient care at baseline

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive treatment with lithium for 8 to 16 weeks
- 2 (Type: EXPERIMENTAL): Participants will receive treatment with valproate for 8 to 16 weeks
- 3 (Type: EXPERIMENTAL): Participants will receive treatment with risperidone for 8 to 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bowel Preparation for Colonoscopy in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* elderly people aged over 65 years~* elective outpatient colonoscopy~* informed consent~Exclusion Criteria:~* patients who had bowel movements of less than 3 per week during last one month~* patients who have a history of renal dysfunction (abnormal elevation of serum creatinine and electrolyte imbalance)~* patients who have a history of alimentary tract surgery~* patients who have other gastrointestinal diseases that are not suitable for undergoing colonoscopy (gastroparesis, gastric outlet obstruction, ileus, ischemic colitis, megacolon, and toxic colitis)~* patients classified as the American Society for Anesthesiology class III or higher~* Any condition which, in the opinion of the Investigator, places the patient at unacceptable risk if he/she were to participate in the study

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard full-volume PEG (Type: ACTIVE_COMPARATOR): None
- Split-dose full-volume PEG (Type: EXPERIMENTAL): None
- Split-dose low-volume PEG (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Influenza Vaccine in HIV Infected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infected adult on stable first line HAART for more than 3 months or anti-retroviral naïve HIV infected adult with a CD4+ cell count \>100 cells/ml performed within the previous 3 months in relation to the date of randomization.~* Age 18-55 years.~* Willing and able to maintain weekly contact at least during period of April - August (i.e. presupposed influenza period) either through SMS or telephonic contact.~* Willing and able to adhere to study protocol re: attendance to clinic for scheduled and illness visits.~Exclusion Criteria:~* Any contraindication to influenza vaccination, including known allergy to egg.~* Currently on treatment for tuberculosis or received treatment for tuberculosis in the past 6 months.~* History of chronic lung disease which required maintenance therapy either currently or in the past 6 months.~* Any contraindication to intramuscular injections.~* Current known grade 3 or grade 4 laboratory or clinical toxicity as per DAIDS toxicity tables.~* Any previous history of influenza or pneumococcal vaccination.~* Any plan to vaccinate against influenza or pneumococcal disease during the course of the study.~* Plan to emigrate from the study area within the next year.~* On steroid therapy for \>21 days (current or within the past 30 days).~* In the investigators opinion unable to maintain study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): To receive a sub-unit influenza vaccine
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Study subjects were physicians in our primary care network.~* Patients included in the study were identified through our health system's clinical data store with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), diagnosis of atrial fibrillation (427.31) or atrial flutter (427.32)~Exclusion Criteria:~Diagnoses of mitral valve disease (394.x), aortic valve disease (395.x), heart valve transplant (V42.2) or heart valve replacement (V42.3).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Educational Intervention Only (Type: ACTIVE_COMPARATOR): Educational Intervention Only - Educational package was delivered as 2 didactic noon-conferences on atrial fibrillation with a review of up-to-date anticoagulation guidelines for stroke prevention, and distribution of educational materials. Physicians delivering the noon conference series at all of the general internal medicine and primary care practice sites included 3 stroke neurologists, 2 cardiologists, and a general internist (PI) who were co-investigators in this study. Internists who were faculty at the University of Cincinnati and Internal Medicine residents also had an opportunity to participate in the first of the noon conferences in a special Department of Medicine Grand Rounds delivered by the PI.~All practices (intervention and control groups) received the educational package focused on physicians, and clinical and non-clinical staff who would be involved in this QI process.
- Educational Intervention plus Decision Support (Type: EXPERIMENTAL): Educational Intervention plus Decision Support - Physicians in the intervention arm received a practice-level and physician-level summary report via a secure web site designed for patients with treatment recommendations that were discordant with current therapy, along with an explanation for the recommendation, the gain or loss in QALYs predicted by the decision model and the current 2014 ACC/AHA/HRS guidelines. Providers were also reminded of upcoming visits for patients being seen within the next week so they could review their reports and use them in discussions with their patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SUNBURST (Success Using Neuromodulation With BURST) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is 22 years of age or older~* Subject has chronic intractable pain of the trunk and/or limbs~* Subject has a average score of 60 or higher for average daily overall pain on the Visual Analog Scale (VAS) 7 day pain diary~* Subject has attempted best medical therapy and has tried and failed at least three documented medically supervised treatments (including, but not limited to physical therapy, acupuncture, etc.) and has failed medication treatment from at least two different classes~* Subject's pain-related medication regimen is stable 4 weeks prior to the baseline evaluation~* Subject agrees not to add or increase pain-related medication from activation through the 24 week follow-up visit~Exclusion Criteria:~* Subject is currently participating in a clinical investigation that includes an active treatment arm~* Subject has been implanted with a previous neurostimulation system or participated in a trial period for a neurostimulation system~* Subject's overall Beck Depression Inventory II Score is \>24 or has a score of 3 on question 9 relating to suicidal thoughts or wishes at the screening visit~* Subject has an infusion pump or any implantable neurostimulator device~* Subjects with concurrent clinically significant or disabling chronic pain problem that requires additional treatment~* Subject has an existing medical condition that is likely to require repetitive Magnetic Resonance Imaging (MRI) evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor)~* Subject has an existing medical condition that is likely to require the use of diathermy in the future~* Subject's pain originates from peripheral vascular disease~* Subject is immunocompromised~* Subject has documented history of allergic response to titanium or silicone~* Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection~* Female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test)

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Burst Stimulation (Type: EXPERIMENTAL): Burst Stimulation using the Prodigy system
- Tonic Stimulation (Type: ACTIVE_COMPARATOR): Tonic Stimulation using the Prodigy system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra-articular Autologous Bone Marrow Aspirate Injection for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \>=3 months of symptomatic knee OA unresponsive to at least two of the following: activity modification, physical therapy, bracing, assistive devices, acupuncture, non-steroidal anti-inflammatory medications, local steroid injections, and hyaluronic acid injections~* Radiographically confirmed Kellgren-Lawrence I-II knee OA (mild knee OA; no bone-on-bone)~* Age 18-79 years~Exclusion Criteria:~* Presence of loose bodies on baseline magnetic resonance imaging~* Clinically and radiologically confirmed anterior/posterior cruciate ligament deficiences~* History of meniscal injury other than degenerative meniscal tears~* Previous knee surgery~* Presence of a degenerative meniscal tear causing mechanical symptoms such as locking, buckling, or give-way~* Intra-articular injection to affected knee within 6 weeks of intra-articular BMA injection~* Mechanical axis deviation greater than 7 degrees~* Intolerance to acetaminophen or hydrocodone (i.e., Vicodin)~* Use of non-steroidal anti-inflammatory drugs \<1 weeks prior to BMA~* Injection of the joint scheduled for treatment within 3 months of BMA injection~* Body mass index of 30 or more~* History of drug abuse~* Current cigarette smokers~* Current use of systemic steroids~* History of or current alcohol abuse or dependence~* History of anemia, bleeding disorders, or inflammatory joint disease~* Active infection~* Active malignancy per medical or surgical history, diagnosed by primary case physician or treating specialist, undergoing treatment, has undergone treatment, or has declined treatment~* Inability to refrain from statin regimen from 1 month pre-injection to 1 month post-injection~* Pregnancy or breastfeeding at time of treatment~* Participating or planning to participate in a worker's compensation program at the time of treatment or follow-up period~* Pending or planned legal action pertaining to knee pain~* Non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Bone Marrow Aspirate (BMA) Injection (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with PMR, diagnosed according to the criteria of Bird et al~Exclusion Criteria:~* patients with arthritis~* patients with giant cell arteritis~* patients with Parkinson's disease~* patients with hypothyroidism~* patients with scapulohumeral periarthritis~* patients with fibromyalgia~* patients unable to cooperate

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bilateral dry eyes~* Capable of providing written informed consent~Exclusion Criteria:~* Chronic or recurring epistaxis (nosebleeds)~* Uncontrolled systemic disease~* Blood coagulation disorder~* Females who are pregnant, nursing or planning a pregnancy

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intranasal Application (Type: EXPERIMENTAL): Intranasal Tear Neurostimulator device, intranasal application for approximately 3 minutes on Day 0 when the participant experienced an Ocular Discomfort Score (ODS) ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
- Extranasal Application (Type: SHAM_COMPARATOR): Intranasal Tear Neurostimulator device, extranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of previously untreated Ph-positive ALL or previously treated in CR after 1-2 courses of therapy or failure after one course of induction chemotherapy without imatinib mesylate.~2. Age \> or = 15 years. Those \< 15 years of age will be treated under compassionate IND.~3. Zubrod performance status \< or = 2 (ECOG Scale, Appendix A).~4. Adequate liver function (bilirubin \< or = to 3.0 mg/dl, unless considered due to tumor), and renal function (creatinine \< or = to 3.0 mg/dl, unless considered due to tumor).~5. Adequate cardiac function as assessed clinically by physical examination.~6. Signed informed consent.~Exclusion Criteria:~1. Active serious infection not controlled by oral or intravenous antibiotics.~2. Treatment with investigational antileukemic agent or chemotherapy agents in the last 7 days before study entry, unless full recovery from side-effects has occurred or patient has rapidly progressive disease judged life-threatening.~3. Active secondary malignancy other than skin cancer (e.g. basal cell carcinoma or squamous cell carcinoma) than in investigator's opinion will shorten survival to less than 1 year.~4. History of Grade III/IV cardiac problems as defined by the New York Heart Association Criteria.~5. Prior history of treatment with imatinib mesylate.~6. Pregnancy or lactating in women of childbearing potential.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyper-CVAD + Imatinib (Type: EXPERIMENTAL): Imatinib 600 mg orally days 1-14, course 1, \& 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m\^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m\^2 IV day 4; Vincristine 2 mg IV days 4 \& 11; \& Dexamethasone 40 mg IV or orally daily days 1-4 \& 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m\^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m\^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete